3/31 cash on hand was $6.4M - only going up from here Q1 Revenue of $2.5 Million
TORONTO, ON / ACCESSWIRE / May 17, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company"), a specialist in PCR testing dedicated to the early detection of multiple diseases through whole blood, today announced its first-quarter financial results for the three months ended March 31, 2021, and provided an update on its business progress.
The Company generated $2.5M in revenue from COVID testing for the quarter. Net loss for the quarter totaled $7.3M. To reflect the operations of the Company more clearly, management has prepared an analysis of EBITDA and Adjusted EBITDA in the MD&A. As disclosed in the MD&A, the adjusted EBITDA for the quarter was $193,000. As at March 31, 2021, the Company had $6.4 million in cash.